Comparison of pro B-natriuretic peptide in hypertensive patients with and without diastolic dysfunction

Yudistira P Santosa1, Anna Tjandrawati, Noormartany

  • 1Department of Internal Medicine, Faculty of Medicine Atmajaya University, Jl. Pluit Raya no. 2, Jakarta. yudipsan@yahoo.com

Insights

N-terminal pro-B-type natriuretic peptide (NT-pro BNP) levels tend to be higher in hypertensive patients with diastolic dysfunction. This suggests NT-pro BNP may aid in detecting this cardiac condition.

Area of Science:

  • Cardiology
  • Biomarkers
  • Hypertension Research

Background:

  • Diastolic dysfunction is a common complication in hypertensive patients.
  • Early detection of diastolic dysfunction is crucial for timely intervention and management.
  • Current diagnostic methods may have limitations in widespread screening.

Purpose of the Study:

  • To investigate the potential of N-terminal pro-B-type natriuretic peptide (NT-pro BNP) as a biomarker for diastolic dysfunction.
  • To evaluate the correlation between NT-pro BNP levels and the presence of diastolic dysfunction in hypertensive individuals.

Main Methods:

  • A cohort of 39 hypertensive patients with normal systolic function underwent echocardiography.
  • Diastolic dysfunction was identified based on specific echocardiographic mitral flow patterns.
  • NT-pro BNP levels were measured using electrochemiluminescence immunoassay (ECLIA).

Main Results:

  • Twelve out of 39 subjects exhibited normal diastolic function.
  • NT-pro BNP levels were observed to be marginally higher in the group with diastolic dysfunction (P=0.053).
  • Baseline characteristics were comparable between groups, except for uric acid levels.

Conclusions:

  • NT-pro BNP levels show a trend towards elevation in hypertensive patients with diastolic dysfunction.
  • NT-pro BNP may serve as a potential, non-invasive indicator for diastolic dysfunction in this population.
  • Further research is warranted to confirm the diagnostic utility of NT-pro BNP for diastolic dysfunction.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...